Conference & Summit Strategy
Theme definition, positioning and market thesis.
Where pharma, biotech & deep-tech leaders shape what's next.
We design and deliver focused, executive-tier summits that bring researchers, founders, investors and decision-makers into the same room, built around the frontier science actually moving the industry.
What We Do
End-to-end conference platforms.
We deliver specialized, end-to-end conference platforms — from market thesis to on-site execution.
Scientific Agenda Development
Programs shaped around emerging trends and the field's real pain points.
Speaker Engagement
Secure researchers, executives, innovators and investors relevant to each theme.
Sponsorship & Partnerships
Tailored opportunities that place brands directly in front of targeted decision-makers.
Delegate Acquisition
Targeted outreach across pharma, biotech, academia, investment and technology.
Branding, Marketing & On-Site Delivery
Event identity, digital promotion, networking design and flawless logistics.
Founder Profile
Sachin Sravan
Founder & CEO, Pharmasynerg Events
Why we started Pharmasynerg Events
Pharmasynerg Events was started with a clear purpose: to build focused, credible conference platforms where the right people in pharma, biotech, healthcare, investment, and emerging science can meet with intent.
Too many industry events become crowded, unfocused, or overly promotional. We wanted to create a different kind of platform, one built around relevant themes, strong conversations, carefully selected audiences, and practical business outcomes.
Our goal is to help delegates, speakers, sponsors, and partners connect through conferences that are professional, transparent, and genuinely useful to the industries we serve.
0
End-to-end services
under one roof
0
Innovation focus
areas covered
0
Audience segments
across the ecosystem
0
Step delivery model,
research to reception
Upcoming Events
Current conference platforms
Singapore · July 12–14, 2027
NEURO-LOGIC 2027
Precision neuroscience business summit exploring neurotechnology, AI, pharmaceuticals, investment, commercialization and the future of brain health innovation.
View Event →Singapore · July 12–14, 2027
NULLIFY 2027
The world's first dedicated summit on vaccine efficacy limitations, waning immunity, and the science of immunological durability. One question: how do we build protection that holds?
View Event →Zurich · September 13–15, 2027
ADC NEXUS 2027
Global summit on ADC manufacturing, outsourcing, supply chain, fill-finish, CMC strategy and commercialization for senior biopharma and solution-provider leaders.
View Event →Philadelphia · September 21–23, 2027
PARITY 2027
Global biosimilars summit connecting scientific, regulatory, manufacturing, commercial, licensing, investment and policy leaders shaping the next era of biosimilars.
View Event →Previous Events
2022
Vaccines Summit Boston
Vaccines Summit Boston 2024 VSBOSTON24
The annual gathering uniting experts, researchers, policymakers and industry across vaccines and immunization — knowledge sharing, emerging trends and the field's most pressing challenges.
08:30
Welcome Speech
Open08:40
Adrian Hill — Jenner Institute, Oxford UniversityTwo Malaria Vaccines Are Approved: What Next?
Keynote09:25
Philip Dormitzer — GSKFuture Trends in Vaccines Innovation
Keynote10:30
Alessandro Sette — La Jolla Institute for Immunology, UCDivision of Vaccine Discovery
Keynote11:15
Trina Racine — VIDOVaccine Development Centre (VDC): a BSL-3 capable GMP manufacturing facility
Keynote12:00
Rama Rao Amara — Emory Vaccine Center
Keynote12:45
Lunch
Break14:00
Jacob Glanville — CentivaxEliciting universal immune responses through concentration-conservation coupling: influenza, coronaviruses, HIV & snake venom
Keynote14:45
Denise L Faustman — Massachusetts General Hospital
Keynote15:50
Mark C Poznansky — Vaccine & Immunotherapy Center, MGHA target-agnostic self-assembling vaccine platform for infectious diseases & cancer
Keynote16:35
Daniel Salmon — Institute for Vaccine Safety, Johns Hopkins
Keynote20:00
Networking Dinner
Network08:30
Victor Suarez — Blu Zone Bioscience & Supply Chain Solutions
Keynote09:15
Derek O'Hagan — GSKAdvances in Vaccine Adjuvants
Keynote10:20
Victor Suarez — Blu Zone BiosciencePanel: Individualized Neoantigen Therapy (INT) for cancer — clinical development, FDA, demand & supply chain
Panel11:20
Kevin P Killeen — MatrivaxMVX01: a global, serotype-independent pneumococcal vaccine candidate
Keynote12:05
Arthur M Krieg — UMass Chan RNA Therapeutics InstituteNucleic acid immunity, innate immunity, and vaccine design
Keynote12:50
Lunch
Break14:00
Lloyd Jeffs & Ying Yu — Cytiva / Precision NanoSystemsStrategies & solutions for succeeding in RNA vaccine development
Keynote15:00
Dan Barouch — Harvard Medical School
Keynote16:00
Tamir Tuller — Tel Aviv UniversityVaccine Development & Design
Session16:25
Yingxia Wen — CSLSelf-amplifying mRNA vaccine development against influenza
Session16:50
Charles Jones — PfizerThe evolution of the adult vaccine market: a holistic perspective
Session17:15
Renhuan Xu — ARV TechnologiesAn mRNA-based HSV vaccine: complete protection against HSV-1 & HSV-2
Session08:30
Rebecca Loomis — GSKIndustry collaboration to sustainably develop vaccines against neglected diseases
Session08:55
Andrew Cornforth — Corner TherapeuticsHyperactivation of dendritic cells & bridging the TH1/TH2 gap
Session09:20
Charles Pavia — NYIT College of Osteopathic MedicineNewly developed vaccines for preventing Lyme disease
Session09:45
Ming Tan — UC Department of PediatricsNorovirus inner shell as a platform for pseudovirus-nanoparticle vaccines
Session10:10
Tzachi Pilpel — Weizmann Institute of ScienceTowards a multi-strain vaccine design strategy
Session11:00
Lori Panther — ModernamRNA-1647 CMV vaccine: Phase 2 safety & immunogenicity
Clinical11:25
Bijan Almassian — CaroGen CorporationCARG-2020 for treatment & prevention of solid tumors
Clinical11:50
Junhua Pan — Hubei University of TechnologySARS-CoV-2 evolution & antibody evasion in an immunocompromised host
Clinical12:15
Njoh Andreas Ateke — Expanded Program on ImmunizationMobile technology for AEFI surveillance during new vaccine introduction, Cameroon
Safety12:40
Lunch
Break14:00
Christopher Locher — Versatope TherapeuticsA novel broad-strain influenza vaccine using nano-vesicles
Immunology14:25
Margherita Coccia — GSKAdjuvant systems: trends, challenges & success stories
Immunology14:50
Prakash Bhuyan — Aerium TherapeuticsThe next generation of mAbs for the prevention of COVID
Immunology15:15
Juliana Melgaço — FIOCRUZ, BrazilC-lectin expression & immune response after vaccination and infection
Immunology15:40
Vjollca Konjufca — Southern Illinois UniversityProtective immunity in the female reproductive tract via oral nanolipoparticle MOMP antigen
Immunology16:05
John Fulkerson — MesoScalePrecise biomarker & correlate evaluation in advanced development
ImmunologyVaccines Summit Boston 2023 VSBOSTON23
A three-day vaccine R&D program across cancer vaccines, live attenuated platforms, HIV, COVID-19, RNA and subunit vaccines, immune profiling, vaccine design, delivery systems, bioprocessing, adjuvants and emerging diseases.
08:00
Inaugural Ceremony
Open08:10
Don J. Diamond — City of HopeDevelopment of CMV-MVA-Triplex vaccine for reduction of cytomegalovirus complication post-transplantation
Keynote09:00
Adrian V. S. Hill — The Jenner Institute, University of Oxford
Keynote09:50
Refreshment Break
Break10:00
Wim Van Criekinge — myNEOExploring and validating clinical validity of lncRNAs as a novel source of immunogenic targets for immunotherapy
Cancer10:30
Eli Gilboa — University of MiamiVaccination against a common set of neoantigens induced in tumors and pathogen infected cells
Cancer11:00
Judith Alamares-Sapuay — SanofiOptimization and characterization of a live attenuated respiratory syncytial virus vaccine candidate
RSV11:30
Pirouz Daftarian — Crown Bioscience, MBLI and JSR Life SciencesToday's metrics of immunogenicity of cancer vaccines
Talk12:00
Genoveffa Franchini — National Cancer Institute, NIHHIV vaccine candidate efficacy via enhanced NK and monocyte function
HIV13:00
Lunch
Break14:00
Sarita K. Acharya — United States PharmacopeiaEnsuring quality and safety of mRNA vaccines today and tomorrow
mRNA14:30
Kun Zhou — GeneLeap BiotechA novel mRNA-based therapeutic vaccine to target HPV16-associated cervical lesions
mRNA15:00
Vira Bitko — RVAC MedicinesDevelopment of RSV mRNA vaccine
RSV15:30
Don J. Diamond — City of Hope / GeoVaxAssessment of Geo-CM04S1 for prevention of COVID-19 in immunocompromised cell therapy patients
COVID-1916:10
Feng Xuan — Spear BioA novel ultrasensitive cell-free SARS-CoV-2 neutralizing antibody assay
Assay17:40
Poster Presentation
Poster20:00
Gala Networking Dinner
Network08:00
Sabine Hauck — Leukocare AGNext generation in formulation development for vaccines
Keynote08:50
William R. Jacobs Jr. — Albert Einstein College of MedicineCurrent progress towards a new tuberculosis vaccine
Keynote09:40
Refreshment Break
Break09:50
Alexander Bukreyev — University of TexasImmune response to mRNA vaccines
Immune10:20
Aaron Esser-Kahn — University of ChicagoEngineering signal processing of innate immune cells
Design10:50
Magdalena Tary-Lehmann — Cellular Technology LimitedImmunogenicity assessment in support of gene therapy programs
Profiling11:20
De-Chu Christopher Tang — VaxDomeBroad-spectrum vaccine-antiviral hybrid without constraints imposed by viral mutations
Design11:50
Joseph G. Joyce — MerckDevelopment and clinical assessment of a novel 21-valent pneumococcal conjugate vaccine
Clinical12:50
Lunch
Break13:50
Mark Emalfarb — Dyadic InternationalTransforming manufacturing and closing the technology gap in least developed countries
Manufacturing14:20
Kevin P. Killeen — MatrivaxMVX01: a global, serotype-independent pneumococcal protein fusion vaccine candidate
Bacterial14:50
Thorsten Vogel — SanofiProof of concept of multivalent/octavalent vaccine platforms in naive ferrets
Influenza15:20
Robert Dillman — AIVITA BiomedicalClinical progress with personal dendritic cell vaccines for cancer and COVID infection
Clinical15:50
Lynda Tussey — Vaxess TechnologiesPhase 1 clinical evaluation of VX-103, a sustained-release patch-based influenza vaccine
Delivery16:30
James Z. Deng — MerckAnalytical strategies for characterization of multi-valent pneumococcal conjugate vaccine
QC17:00
Mic McGoldrick — Merck / IFPMAAccelerating access to vaccines: next steps beyond the pandemic
Access17:30
Matthew A. Coleman — Lawrence Livermore National LaboratoryCell-free expression of Chlamydial membrane proteins for antigen discovery
Talk08:00
Trudy Morrison — University of Massachusetts Chan Medical SchoolThe RSV G protein enhances immune responses to the RSV F protein in an enveloped virus-like particle vaccine candidate
RSV08:30
Christopher P. Locher — Versatope TherapeuticsStructure and function of a broad-strain influenza vaccine using nano-vesicles
Influenza09:30
Refreshment Break
Break09:40
Jun Lin — The University of TennesseeEnterobactin-based immune intervention against Gram-negative pathogens
Bacterial10:10
Selvakumar Subbian — Rutgers UniversityImmune response of BCG vaccination shaped by pathogenic Mycobacterium tuberculosis inoculum
TB10:40
Chinnaswamy Jagannath — Houston Methodist Research InstituteNew generation adenoviral and mRNA-based tuberculosis vaccines
TB11:10
Lei Jin — University of FloridaMucosal vaccine for the aged: decoding cyclic dinucleotide adjuvanticity
Adjuvant11:40
Adam E. Snook — Thomas Jefferson UniversityAdjuvant vaccines to prevent GI cancer recurrence
Cancer12:10
Joseph M. Vinetz — Yale University School of MedicineUsing bacterial genomics to enable vaccine development for an emerging zoonotic infectious disease
Emerging13:10
Lunch
Break
Gold
Silver
Bronze
Collaborator
Partner
Session tracks
Cancer vaccinesHIV vaccinesCOVID-19 vaccine R&DDNA, RNA & subunit vaccinesImmune profilingVaccine designClinical trialsDelivery systemsBioprocessing & manufacturingInfluenza & respiratoryBacterial, TB & malarial vaccinesVaccine adjuvantsEmerging diseases
Vaccines Summit Ohio 2021 VIRTUAL
The inaugural Vaccines Summit — a global virtual gathering across infectious disease, immuno-oncology, bacterial & viral vaccines, emerging diseases and vaccine hesitancy.
Keynote Session
Gregory A. Poland — Mayo Vaccine Research Group
KeynoteLuis Rios-Nogales — Rational Vaccines
KeynotePeter Nara — Keystone BioDecoding immune-evading mechanisms of pathogens: re-ordering of immuno-dominance for improved immunity
KeynoteKevin Killeen — MatrivaxMVX01: a serotype-independent pneumococcal protein fusion vaccine candidate
KeynoteDenise Faustman — Massachusetts General HospitalThe BCG vaccine for off-target applications: type 1 diabetes, COVID, autoimmunity & Alzheimer's
KeynoteYehuda Shoenfeld — Sheba Medical CenterVaccine and autoimmunity
KeynoteAhmed Bouzidi — Immunal Therapeutics
KeynoteAndrew Lees — Fina BioSolutionsDevelopment of EcoCRM® CRM197 carrier protein
KeynoteJacob Glanville — CentivaxProvoking spectrum immune responses through concentration-conservation coupling
KeynoteViral Vaccines
De-chu Christopher Tang — VaxDomeBioengineered adenovirus particles & infection with unrelated pathogens
TalkMing Tan — UC Department of PediatricsNorovirus capsid protein-derived nanoparticles as versatile vaccine platforms
TalkSabine Hauck — Leukocare AGAlgorithm-based stabilization of viral vaccines & viral vector formulations
TalkStefan Metz — University of North CarolinaThe re-design of flavivirus envelope subunit vaccine candidates
TalkAnimal Models & Clinical Development
S. Louise Cosby — Agri-Food and Biosciences InstituteLarge animal models for veterinary & human vaccines
TalkJames E. Samuel — Texas A&M UniversityVaccines against the zoonotic illness Q fever in multiple animal models
TalkMagdalena Tary-Lehmann — Cellular Technology LimitedImmunogenicity assessment for vaccine therapy programs — use of ELISPOT
TalkImmuno-Oncology · Moderator: Mahin Khatami
Mahin Khatami — National Cancer InstituteImmune & bioenergetics of cancer, drugs and vaccines: future outlooks
KeynoteGeert Vanden Bossche — CoimevaIdentifying target antigens for infectious, immune-mediated & cancer diseases
KeynoteStephen Johnston — Arizona State UniversityRNA-processing-derived frameshift neoantigens for cancer vaccines
TalkVincent K. Tuohy — Lerner College of MedicinePrimary immunoprevention of adult-onset cancers
TalkGiulio Tarro — Beaumont Bonelli FoundationFrom polio vaccines to oncogenic viruses
TalkMichael G Hanna — VaccinogenPersonal cancer vaccines & antigen-competition-driven immune editing
TalkPravin Kaumaya — The Ohio State UniversityCombining cancer vaccines & immuno-oncology strategies
TalkJung S. Huang — Saint Louis UniversityLYVE-1 as a novel immuno-oncology target for cancer vaccines
TalkRobert O. Dillman — AIVITA BiomedicalPatient-specific therapeutic vaccines from autologous cancer-initiating cells
TalkArabinda Chaudhuri — IISERIn vivo dendritic-cell-targeted DNA vaccination for cancer
TalkTimothy W. Phares — Leidos
TalkBacterial Vaccine
Mariagrazia Pizza — GSK VaccinesThe 4CMenB vaccine: from design to real-world data
TalkLarry S. McDaniel — University of Mississippi Medical CenterPneumococcal vaccines & changing pneumococcal ecology
TalkIsis Kanevsky — PfizerAdvances in bacterial vaccine development
TalkTobias Kaeser — North Carolina State UniversityChlamydia suis pre-exposed pigs as a model for C. trachomatis vaccine development
TalkMatthew Coleman — UC DavisA nanoscaffold-based Chlamydia trachomatis vaccine
TalkRebecca Ingram — Queen's University BelfastInnate lymphoid cell memory protects against bacterial infection
TalkDavid E. Briles — University of Alabama at BirminghamPolysaccharide-conjugate vaccines & pneumococcal meningitis
TalkInfluenza, RSV & TB
Martha A. Alexander-Miller — Wake Forest School of MedicineA safe & efficacious influenza vaccine for newborns
TalkMarie Mazur — Vaccine Strategic AdvisorPandemic influenza: preparing through seasonal readiness
TalkSarah Ives — CentivaxComputational immunology enables broad-spectrum vaccines
TalkJon Heinrichs — Sanofi PasteurPrevention of RSV in children
TalkJaved N Agrewala — Indian Institute of TechnologyLipidated promiscuous peptide vaccine to control TB
TalkNew Vaccine Development
M. Gordon Joyce — Henry M. Jackson FoundationStructure-based vaccine design
TalkVjollca Konjufca — Southern Illinois UniversityImmunity in the female reproductive tract via per-oral antigen administration
TalkTom Lake — VaxxasA microarray patch for skin delivery of vaccines
TalkGavin Wright — Wellcome Sanger InstituteAn invariant Trypanosoma vivax vaccine antigen inducing protective immunity
TalkMartin J. D'Souza — Mercer UniversityMicroneedle transdermal microparticulate vaccines: gonorrhea vaccine development
TalkRobert DeWitte — ElarexRecent advances in stabilizing biologicals & vaccines
TalkLi Shi — ZerunBioA VLP-based EV71 vaccine
TalkRitu Chakravarti — University of ToledoA prophylactic vaccine for rheumatoid arthritis
TalkVidya Sivaraman — Nationwide Children's HospitalImproving vaccination in immunocompromised patients
TalkJiang Zhu — Scripps Research InstituteSingle-component self-assembling protein nanoparticle (SApNP) vaccines
TalkAli I. Fattom — Blue Willow BiologicsNanoVAX® mucosal adjuvant for intranasal & epicutaneous vaccines
TalkEmerging Diseases
Alexander Bukreyev — UT Medical BranchmRNA-1273 efficacy in a severe COVID-19 model
TalkAdel Talaat — University of Wisconsin-MadisonNanovaccines for rapid response to emerging infections
TalkSubhash C. Basak — University of MinnesotaComputer-aided peptide vaccine design for Zika & COVID-19
TalkAnand Anbarasu — Vellore Institute of TechnologyVaccine re-purposing to prevent emerging infections
TalkAnamika Basu — Gurudas CollegeImmunoinformatics strategies for coronavirus vaccine design
TalkMichael Har-Noy — Immunovative TherapiesAllo-priming as a universal anti-viral vaccine
TalkPirouz Daftarian — JSR Life SciencesSARS-CoV-2-specific CD4+ T cells as a surrogate of prolonged immunity
TalkVaccine Hesitancy & Safety
Caroline M. Poland — Poland and Associates ConsultingVaccine hesitancy
TalkPierre A. Morgon — MRGN AdvisorsNew technologies enabling superior acceptability of vaccines
TalkTsuriel Rashi — Ariel UniversityJewish ethics regarding vaccination
TalkBarbara Lasagna — GSKVaccine companies as partner vs vaccine hesitancy
TalkTilahun Yilma — UC DavisEnhancing the safety & efficacy of live recombinant vaccines
Talk
Attendee Demographics
VSOHIO21 drew an international vaccine audience.
The virtual summit brought together delegates across research, service providers, clinical trials, manufacturing, academia and specialist media, with attendees from 25 countries.
25
countries represented
Industry Mix
Company and organization type
Job Function
Seniority and role profile
International Audience
Delegates joined from 25 countries, with most North American attendees coming from the USA and Canada.
25
countries represented
Largest represented country groups noted in the source included Italy, the UK, China, Germany, Australia and India.
USACanadaUKGermanyItalySpainFranceIndiaChinaJapanAustraliaAustriaBrazilSouth AfricaSingaporeMexicoSwitzerlandRussiaKoreaOthers
Advancing Gene Therapy 2022 AGT
BSC's inaugural gene therapy summit — strategy and program development across analytical development, manufacturing, delivery platforms, gene editing, cell therapy and commercialization, on the path to safe advanced therapies.
08:36
Christian Mueller — Sanofi GenzymeChallenges of traditional AAV delivery & the promise of next-generation approaches
Keynote09:16
Joerg Ahlgrimm — The Discovery LabsHow a comprehensive outsourcing solution accelerates speed to milestone
Keynote10:41
Panel — Gene Therapy for Neurological DisordersMod. Frank Sasinowski · J. Day (Stanford), K. Flanigan (Nationwide Children's), S. Rico (Encoded)
Panel11:41
Shane Hegarty — AXONIS TherapeuticsIn vivo phenotypic screens to identify gene therapies for neurological disorders
Talk12:06
Lunch
Break13:01
Panel — Rare Disease Targets & Bench-to-Bedside TranslationMod. Alison Schecter (Axcella) · T. Miller (Forge Biologics), J. Rininger (Latham Biopharm)
Panel14:01
Dan Wang — UMass Chan Medical SchoolTargeting common causes in rare diseases
Talk14:26
Jeff Galvin — American Gene TechnologiesGene & cell therapy revolution: the future of pharmaceutical
Keynote15:21
Anthony Johnson — KodikazZipCodes: the next generation of gene therapy in oncology
Talk15:46
Ram I. Mahato — University of Nebraska Medical CenterRedox-responsive nanoparticles for codelivery of miRNA & gemcitabine in pancreatic cancer
Talk16:11
George Tetz — CLS TherapeuticsFirst-in-class anticancer AAV-based (LK03) gene therapy via DNase I expression
Talk16:36
Vibha Jawa — Bristol Myers SquibbRisk-based bioanalytical & clinical immunogenicity strategy for gene therapies
Talk17:01
Mary Kosta — Lymphoma CanadaGene therapy for cancer & immunotherapy
Talk17:26
Khalid Shah — BWH, Harvard Medical SchoolCell-based immune therapies for solid tumours
Talk19:01
Networking Dinner
Network08:30
Panel — Analytical Development & ManufacturingMod. Kelly Quesada (Homology) · A. Strancar (BIA), K. Raineri (AVROBIO), M. Pujols (Andelyn)
Panel09:31
Syed Reza — NOF AmericaCOATSOME SS-Lipids: biodegradable, ionizable lipids for mRNA therapeutics
Talk09:56
Joseph Rininger — Latham Biopharm GroupViral vector demand versus CDMO capacity
Talk10:51
Emily Moran — The Discovery LabsIndustrializing academic processes from development to manufacturing
Talk11:16
Mark A. Kay — Stanford UniversityNew AAV vectors for gene transfer & genome editing in vivo
Talk11:41
Ales Strancar — BIA Separations (Sartorius)AAV manufacturing and in-process controls
Talk12:06
Iker Badiola — University of the Basque CountrySorbitan-ester nanosystem for miRNA delivery as antiangiogenic therapy
Talk12:30
Lunch
Break13:31
Arun Srivastava — University of FloridaNextGen, GenX & Opt AAV vectors for human gene therapy
Talk13:56
Richard Heller — University of South FloridaGene electrotransfer of plasmid DNA as a delivery approach
Talk14:21
Audrey Greenberg — The Discovery LabsCreating a successful bio innovation hub
Keynote15:01
Clark Pan — PfizerBuilding an industry-leading gene therapy pipeline
Keynote15:41
Christian Mueller — Sanofi GenzymeStrategy for Sanofi's gene therapy portfolio
Keynote16:21
Angela Columbano — GenethonA pipeline of gene therapies for neuromuscular diseases
Talk17:01
Rachel Legmann — RepligenIntensifying viral vector upstream & downstream manufacturing
Talk17:26
Jean-Simon Diallo — Virica BiotechBoosting gene therapy vector production with viral sensitizer molecules
Talk17:51
Ted L Liberti — Biomagnetic SolutionsGLP & GMP cell-selection systems for CAR-T & gene therapy products
Talk18:16
Susan G. L. Glovsky — Hamilton, Brook, Smith & ReynoldsErecting and tearing down patent barriers to market access
Talk18:41
Shailesh Maingi — KineticosThe future of gene therapy
Talk09:01
Panel — Gene Editing & CRISPR
Panel10:01
Ana Moreno — Navega TherapeuticsLong-lasting analgesia via targeted in situ repression of Nav1.7
Talk10:51
Devyn M. Smith — Arbor BiotechnologiesNext-generation genome editors tailored for patient diseases
Talk11:16
Will Chou — AruvantA differentiated cell therapy approach for sickle cell disease
Keynote12:06
Dan Shelly — Prescient TherapeuticsOmniCAR development for a universal CAR-T therapy
Talk12:31
Farideh Bischoff — FreMon ScientificA rapid dry precision thawing platform for point-of-care cellular therapies
Talk12:55
Lunch
Break14:01
Michele Stone — Kriya TherapeuticsChallenges in nonclinical pharmacology & toxicology gene therapy studies
Talk14:01
Daniel Kavanagh — WCG IRBEthical & biosafety review of gene therapy clinical trials
Talk14:26
Magali Taiel — GenSight BiologicsLumevoq gene therapy in Leber hereditary optic neuropathy (LHON)
Talk14:51
Samarendra Mohanty — Nanoscope TherapeuticsOptogenetic therapeutics for vision restoration
Talk15:16
Héctor de la Riva Domínguez — NovartisAdvancing gene therapy in rare ocular diseases
Talk15:41
Posters — Jake McAndrew (Distek) & Sarah Blackmore (Pall Biotech)Bioprocess optimization & depth-filter clarification for AAV culture
Posters
Platinum
Bronze
Media
Who was there
American Gene TechnologiesAlexionAndelyn BiosciencesAruvantAskBioAVROBIOAxcella HealthBiogenBiomagnetic SolutionsBioMarinBraccoBristol Myers SquibbThe Discovery LabsEncoded TherapeuticsForbionForge BiologicsFreMon ScientificGenethonGenSight BiologicsHomology MedicinesHyman, Phelps & McNamaraJaguar Gene TherapyJohnson & JohnsonKineticosKite PharmaKriya TherapeuticsLatham Biopharm GroupLogicBioLymphoma CanadaMerckNeurophth TherapeuticsNovartisOmega TherapeuticsPfizerPrescient TherapeuticsRepligenQiagenSelecta BiosciencesTakedaThermo Fisher ScientificVertex PharmaceuticalsVerve TherapeuticsVirica BiotechVycellix
How We Work
From market research to the closing reception.
- 01
Research the market and stakeholder needs.
- 02
Define a focused theme, audience and business objective.
- 03
Build a program of sessions, panels and curated networking.
- 04
Engage speakers, sponsors and delegates.
- 05
Deliver an executive experience that drives outcomes.
Strategic Networking
The conference is the room. The value is the connection.
The most valuable part of any summit is the quality of connections created before, during and after the event.
Curated Industry Communities
Focused sectors that make every introduction relevant.
Executive-Level Engagement
Direct access across leaders, researchers, investors and founders.
Structured Experiences
Roundtables, curated introductions, receptions and private meetings.
Relationship-Driven
Quality over quantity, with room for real conversations.
Cross-Disciplinary
Pharma, biotech, neuroscience, AI health and investment in one orbit.
In the room
DelegatesSpeakersSponsorsInvestorsStartupsPharma LeadersBiotech ExecsResearchersProviders
Our goal is industry platforms where delegates, sponsors, speakers and partners engage in conversations that lead to real business, scientific and professional outcomes.
Who We Serve
Pharmaceutical & biotechnology companies, gene & cell therapy developers, neurotech and AI health innovators, CDMOs & manufacturers, investors & VC, academic researchers, clinical development teams, regulatory and market access professionals, and solution providers.
Sponsor & Partner
Visibility with exactly the right audience.
Executive-level visibility, targeted industry audiences, and positioning within high-growth areas of life sciences and healthcare.
Request Sponsorship Information →- Executive-level brand exposure
- Targeted audience engagement
- Thought leadership opportunities
- Networking access
- Lead generation potential
- Digital & on-site visibility
- Strategic partnership opportunities
Contact
Connect with Pharmasynerg Events
For delegate queries, sponsorships, partnerships or general enquiries, reach us directly.
Address
RAM SVR, Plot No 4/2,
Madhapur, HUDA Techno Enclave,
HITEC City, Hyderabad,
Telangana 500081